Anti-VEGF agents in the treatment of diabetic macular edema

Diabetic macular edema (DME) is a common complication associated with the loss of visual acuity in diabetic patients. Intravitreal injections of vascular endothelium growth factor (VEGF) inhibitors (anti-VEGF therapy) have been proposed recently as a new treatment option for patients with DME. In th...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Vladimir Iosifovich Konenkov, Vadim Valerievich Klimontov, Valeriy Vyacheslavovich Chernykh, Nadezhda Viktorovna Tjan
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2013
Materias:	diabetic macular edema vascular endothelium growth factor ranibizumab bevacizumab pegaptanib afliberсept Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/742d86e339d947eb8af79c385b38765a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:742d86e339d947eb8af79c385b38765a
record_format	dspace
spelling	oai:doaj.org-article:742d86e339d947eb8af79c385b38765a2021-11-14T09:00:18ZAnti-VEGF agents in the treatment of diabetic macular edema2072-03512072-037810.14341/DM2013478-84https://doaj.org/article/742d86e339d947eb8af79c385b38765a2013-12-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/3871https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378Diabetic macular edema (DME) is a common complication associated with the loss of visual acuity in diabetic patients. Intravitreal injections of vascular endothelium growth factor (VEGF) inhibitors (anti-VEGF therapy) have been proposed recently as a new treatment option for patients with DME. In this review we summarized results of randomized clinical trials of VEGF inhibitors in DME patients. The results indicate that all studied inhibitors (ranibizumab, bevacizumab, pegaptanib and aflibersept) reduce the retinal thickness and improve of visual acuity in DME when are used as a monotherapy or in combination with the laser treatment. Optimal course duration and effectiveness predictors of anti-VEGF therapy in DME should be elucidate in the future studies.Vladimir Iosifovich KonenkovVadim Valerievich KlimontovValeriy Vyacheslavovich ChernykhNadezhda Viktorovna TjanEndocrinology Research Centrearticlediabetic macular edemavascular endothelium growth factorranibizumabbevacizumabpegaptanibafliberсeptNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 16, Iss 4, Pp 78-84 (2013)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	diabetic macular edema vascular endothelium growth factor ranibizumab bevacizumab pegaptanib afliberсept Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	diabetic macular edema vascular endothelium growth factor ranibizumab bevacizumab pegaptanib afliberсept Nutritional diseases. Deficiency diseases RC620-627 Vladimir Iosifovich Konenkov Vadim Valerievich Klimontov Valeriy Vyacheslavovich Chernykh Nadezhda Viktorovna Tjan Anti-VEGF agents in the treatment of diabetic macular edema
description	Diabetic macular edema (DME) is a common complication associated with the loss of visual acuity in diabetic patients. Intravitreal injections of vascular endothelium growth factor (VEGF) inhibitors (anti-VEGF therapy) have been proposed recently as a new treatment option for patients with DME. In this review we summarized results of randomized clinical trials of VEGF inhibitors in DME patients. The results indicate that all studied inhibitors (ranibizumab, bevacizumab, pegaptanib and aflibersept) reduce the retinal thickness and improve of visual acuity in DME when are used as a monotherapy or in combination with the laser treatment. Optimal course duration and effectiveness predictors of anti-VEGF therapy in DME should be elucidate in the future studies.
format	article
author	Vladimir Iosifovich Konenkov Vadim Valerievich Klimontov Valeriy Vyacheslavovich Chernykh Nadezhda Viktorovna Tjan
author_facet	Vladimir Iosifovich Konenkov Vadim Valerievich Klimontov Valeriy Vyacheslavovich Chernykh Nadezhda Viktorovna Tjan
author_sort	Vladimir Iosifovich Konenkov
title	Anti-VEGF agents in the treatment of diabetic macular edema
title_short	Anti-VEGF agents in the treatment of diabetic macular edema
title_full	Anti-VEGF agents in the treatment of diabetic macular edema
title_fullStr	Anti-VEGF agents in the treatment of diabetic macular edema
title_full_unstemmed	Anti-VEGF agents in the treatment of diabetic macular edema
title_sort	anti-vegf agents in the treatment of diabetic macular edema
publisher	Endocrinology Research Centre
publishDate	2013
url	https://doaj.org/article/742d86e339d947eb8af79c385b38765a
work_keys_str_mv	AT vladimiriosifovichkonenkov antivegfagentsinthetreatmentofdiabeticmacularedema AT vadimvalerievichklimontov antivegfagentsinthetreatmentofdiabeticmacularedema AT valeriyvyacheslavovichchernykh antivegfagentsinthetreatmentofdiabeticmacularedema AT nadezhdaviktorovnatjan antivegfagentsinthetreatmentofdiabeticmacularedema
_version_	1718429586553831424

Anti-VEGF agents in the treatment of diabetic macular edema

Ejemplares similares